Atossa Therapeutics (NASDAQ:ATOS) traded higher on Monday after H.C. Wainwright launched its coverage with a Buy rating and a $4 per share target, citing the prospects of its lead asset, Z-Endoxifen, an active metabolite of the pro-drug Tamoxifen.
HCW analyst Emily Bodnar notes that a mid-stage trial for Z-Endoxifen is underway for the reduction of measurable breast density (MBD), with initial data expected in the second half of the year. MBD is a condition with no FDA-approved therapies despite its link to breast cancer.
In another Phase 2 study, Z-endoxifen is under investigation for neoadjuvant breast cancer, with topline data expected in H2 2024.
Ahead of data readouts this year, the analyst pointed to “significant upside potential” for the stock as the company’s shares are trading near cash levels, implying no value for its pipeline.
“With the company’s share price trading near cash levels, we believe investors are currently attributing no value to the pipeline, and we see significant upside potential on 2H24 catalysts,” Bodnar pointed out.
“We believe data readouts in 2024 could provide continued rationale for use in the neoadjuvant and preventative spaces and Zendoxifen could be more effective and safer than tamoxifen,” she added.